CSL Behring: FDA approval for Hizentra (20% liquid) 50mL//10gm prefilled syringe to treat primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy
Global biotechnology leader CSL Behring announced the FDA approved a 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid)
Read full article »
CSL Behring is a Pennsylvania-based biopharmaceutical company that develops protein-based therapies for the treatment of bleeding disorders and pulmonary disease.
Read more